Combined hormonal contraception in prevention of tumorous diseases


Authors: Tomáš Fait
Authors‘ workplace: Gynekologicko-porodnická klinika 1. lékařské fakulty UK a VFN v Praze, přednosta prof. MUDr. Alois Martan, DrSc.
Published in: Prakt Gyn 2013; 17(2): 153-155
Category: Oncogynecology: Review Article

Overview

Combined hormonal contraception has protective effect against ovarian cancer. It decreases by 30–50 %. Risk of endometrial cancer is lowering by 50–70 %. Strength of protection is positive related to length of combined contraception use. After ceasing oral contraception the primary preventive effect persists for minimally 20 years.

Key words:
colorectal carcinoma – endometrial carcinoma – hormonal contraception – ovarian carcinoma


Sources

1. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371(9609): 303–314.

2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95(3): 385–389.

3. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. Br Med J 2007; 335(7621): 651.

4. Narod SA, Risch H, Moslehi R et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339(7): 424–428.

5. McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004; 160(7): 613–618.

6. Whittemore AS, Balise RR, Pharoah PD et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004; 91(11): 1911–1915.

7. Modan B, Hartge P, Hirsh-Yechezkel G at al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4): 235–240.

8. Tworoger SS, Fairfield KM, Colditz GA et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166(8): 884–901.

9. Ness RB, Grisso JA, Vergona R at al. Oral contaceptives, other methods of contraceptin, and risk reduction for ovarian cancer. Epidemiology 2001; 12(3): 307–312.

10. Ness RB, Rhiannon CD, Edwards RP et al. Contraception methods, beyond oral contraceprives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011; 21(3): 188–196.

11. Grimbizis GF, Tarlatzis BC. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gyn 2010; 24(1): 29–38.

12. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and metaanalysis. Hum Reprod Update 2011; 17(1): 55–67.

13. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. Hum Reprod 1997; 12(9): 1851–1863.

14. Fernandez E, La Vecchia C, Balducci A et al. Oral contraceptives and colorectal cancer risk: a metaanalysis. Br J Cancer 2001; 84(5): 722–727.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account